0	8	Evidence	evidence	NN
9	12	for	for	IN
13	14	a	a	DT
15	25	polyclonal	polyclonal	JJ
26	34	etiology	etiology	NN
35	37	of	of	IN
38	44	palmar	palmar	JJ
45	57	fibromatosis	fibromatosis	NN
57	58	.	.	.

60	61	X	X	NNP
62	72	chromosome	chromosome	NN
73	85	inactivation	inactivation	NN
86	94	patterns	pattern	NNS
95	97	at	at	IN
98	101	the	the	DT
102	110	androgen	androgen	NN
111	119	receptor	receptor	NN
120	125	locus	locus	NN
126	130	were	be	VBD
131	140	evaluated	evaluate	VBN
141	143	to	to	TO
144	153	determine	determine	VB
154	163	clonality	clonality	NN
164	166	in	in	IN
167	181	microdissected	microdissecte	VBN
182	190	lesional	lesional	JJ
191	197	tissue	tissue	NN
198	201	and	and	CC
202	204	in	in	IN
205	215	leukocytes	leukocyte	NNS
216	220	from	from	IN
221	222	2	2	CD
223	228	women	woman	NNS
229	233	with	with	IN
234	243	Dupuytren	Dupuytren	NNP
243	245	’s	's	POS
246	253	disease	disease	NN
253	254	.	.	.

255	258	The	the	DT
259	265	tissue	tissue	NN
266	270	from	from	IN
271	275	both	both	DT
276	284	patients	patient	NNS
285	294	generated	generate	VBD
295	296	a	a	DT
297	307	polyclonal	polyclonal	JJ
308	315	pattern	pattern	NN
316	318	of	of	IN
319	320	X	X	NNP
321	331	chromosome	chromosome	NN
332	344	inactivation	inactivation	NN
345	347	of	of	IN
348	351	the	the	DT
352	357	human	human	JJ
358	366	androgen	androgen	NN
367	375	receptor	receptor	NN
376	380	gene	gene	NN
380	381	.	.	.

382	386	This	this	DT
387	394	finding	finding	NN
395	403	supports	support	VBZ
404	405	a	a	DT
406	416	polyclonal	polyclonal	JJ
417	425	reactive	reactive	JJ
426	433	process	process	NN
434	436	as	as	IN
437	440	the	the	DT
441	451	underlying	underlie	VBG
452	460	etiology	etiology	NN
461	464	for	for	IN
465	471	palmar	palmar	JJ
472	484	fibromatosis	fibromatosis	NN
484	485	.	.	.